{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:55:28Z","timestamp":1793933728830,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["53400277"],"award-info":[{"award-number":["53400277"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017636","name":"Pfizer Inc Centers for Therapeutic Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017636","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ijcard.2022.06.035","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T21:35:03Z","timestamp":1655328903000},"page":"102-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative study"],"prefix":"10.1016","volume":"363","author":[{"given":"Kimon","family":"Stamatelopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Delialis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Georgiopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Irini","family":"Tselegkidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Dialoupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Bampatsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignatios","family":"Ikonomidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Tzortzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kanakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Trougakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2022.06.035_bb0005","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","volume":"40","author":"Emdin","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0010","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0015","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2022.06.035_bb0020","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0025","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0030","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2022.06.035_bb0035","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ijcard.2022.06.035_bb0040","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1002\/ehf2.12793","article-title":"Gateway and journey of patients with cardiac amyloidosis","volume":"7","author":"Dang","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ijcard.2022.06.035_bb0045","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/CIRCRESAHA.119.314862","article-title":"Reactive vasodilation predicts mortality in primary systemic light-chain amyloidosis","volume":"125","author":"Stamatelopoulos","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0050","first-page":"7795","article-title":"Evidence of the presence of amyloid substance in the blood of familial amyloidotic polyneuropathy patients with ATTR Val30Met mutation","volume":"7","author":"Liu","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0055","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000446513","article-title":"Heart failure complicated by alveolar hemorrhage due to vascular collapse and amyloid deposits in wild-type transthyretin amyloidosis","volume":"135","author":"Kido","year":"2016","journal-title":"Cardiology"},{"key":"10.1016\/j.ijcard.2022.06.035_bb0060","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0065","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.exger.2017.06.007","article-title":"Vascular ageing: underlying mechanisms and clinical implications","volume":"109","author":"Laina","year":"2018","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0075","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: an update on diagnosis and treatment","volume":"6","author":"Yamamoto","year":"2019","journal-title":"ESC Heart Failure"},{"key":"10.1016\/j.ijcard.2022.06.035_bb0080","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0085","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/jhh.2017.15","article-title":"Prolactin as a predictor of endothelial dysfunction and arterial stiffness progression in menopause","volume":"31","author":"Georgiopoulos","year":"2017","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0090","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jacc.2014.12.035","article-title":"Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease","volume":"65","author":"Stamatelopoulos","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0095","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1469-7793.2000.t01-1-00263.x","article-title":"The influence of heart rate on augmentation index and central arterial pressure in humans","volume":"525","author":"Wilkinson","year":"2000","journal-title":"J. Physiol."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0100","first-page":"85","article-title":"Estimating cardiac output from blood pressure and heart rate: the liljestrand & zander formula","volume":"51","author":"Koenig","year":"2015","journal-title":"Biomed. Sci. Instrum."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0105","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.ijcard.2022.06.035_bb0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00392-017-1167-1","article-title":"Predictors of survival stratification in patients with wild-type cardiac amyloidosis","volume":"107","author":"Siepen","year":"2018","journal-title":"Clin. Res. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2022.06.035_bb0125","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10741-021-10080-2","article-title":"Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness","volume":"27","author":"Nativi-Nicolau","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0130","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s11906-015-0580-y","article-title":"Influence of vascular function and pulsatile hemodynamics on cardiac function","volume":"17","author":"Bell","year":"2015","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0135","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/eurjhf\/hfp091","article-title":"Endothelium-dependent and -independent vasodilation is more attenuated in ischaemic than in non-ischaemic heart failure","volume":"11","author":"Klosinska","year":"2009","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0140","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1093\/eurheartj\/ehy346","article-title":"Pulsatile arterial haemodynamics in heart failure","volume":"39","author":"Weber","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0145","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/HJH.0000000000002000","article-title":"Noninvasive peripheral vascular function and atrial fibrillation in the general population","volume":"37","author":"B\u00f6rschel","year":"2019","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0150","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jash.2018.06.016","article-title":"Measurement of pulse wave velocity, augmentation index, and central pulse pressure in atrial fibrillation: a proof of concept study","volume":"12","author":"Caluw\u00e9","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.ijcard.2022.06.035_bb0155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2018.04.031","article-title":"Low diastolic blood pressure and adverse outcomes in heart failure with preserved ejection fraction","volume":"263","author":"Tsujimoto","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0160","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jacc.2016.07.754","article-title":"Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control","volume":"68","author":"McEvoy","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0165","article-title":"Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy, open","volume":"3","author":"Damy","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2022.06.035_bb0170","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2022.06.035_bb0175","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0180","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.15252\/emmm.201404190","article-title":"Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity","volume":"6","author":"Guan","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ijcard.2022.06.035_bb0185","doi-asserted-by":"crossref","first-page":"H2305","DOI":"10.1152\/ajpheart.00503.2011","article-title":"Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins","volume":"301","author":"Migrino","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0190","doi-asserted-by":"crossref","DOI":"10.1111\/anec.12749","article-title":"Autonomic dysfunction in cardiac amyloidosis assessed by heart rate variability and heart rate turbulence","volume":"25","author":"Yamada","year":"2020","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0195","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003516","article-title":"Aortic waveform analysis to individualize treatment in heart failure","volume":"10","author":"Wohlfahrt","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"130","key":"10.1016\/j.ijcard.2022.06.035_bb0200","first-page":"256","article-title":"Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction","volume":"2021","author":"Bunsawat","year":"1985","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0205","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00018-019-03357-1","article-title":"Cellular secretion and cytotoxicity of transthyretin mutant proteins underlie late-onset amyloidosis and neurodegeneration","volume":"77","author":"Ibrahim","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0210","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ejhf.1436","volume":"21","author":"Ikonomidis","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ijcard.2022.06.035_bb0215","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10741-015-9471-1","article-title":"The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis","volume":"20","author":"Chow","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0220","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011457","article-title":"Impact of diabetes mellitus on ventricular structure, arterial stiffness, and pulsatile hemodynamics in heart failure with preserved ejection fraction","volume":"8","author":"Chirinos","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ijcard.2022.06.035_bb0225","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10741-014-9466-3","article-title":"Echocardiography in cardiac amyloidosis","volume":"20","author":"Falk","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ijcard.2022.06.035_bb0230","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn Virginia","year":"2020","journal-title":"JACC Heart Failure"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322009330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322009330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:58:21Z","timestamp":1759093101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527322009330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":46,"alternative-id":["S0167527322009330"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.06.035","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.06.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}